FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281562082> ?p ?o ?g. }

• W4281562082 endingPage "779" @default.
• W4281562082 startingPage "771" @default.
• W4281562082 abstract "Purpose Traditional management of metastatic sarcoma primarily relies on systemic therapy, with surgery often used for tumor control. We analyzed the rates of recurrence, overall survival, and treatment complications in patients undergoing either surgical resection or stereotactic body radiation therapy (SBRT) for metastatic sarcoma of the bone and/or soft tissue. Methods and Materials The records of patients with metastatic sarcoma between 2009 and 2020 were reviewed. Local recurrence (LR) was defined as tumor growth or recurrence at the tumor site. Cumulative LR incidence was analyzed accounting for the competing risk of death, and groups were compared using the Gray test. Overall survival (OS) was assessed using the Kaplan-Meier method and log-rank test. Hazard ratios were determined using the Cox proportional hazards model. Results A total of 525 metastatic lesions in 217 patients were analyzed. The mean age of patients was 57 years (range, 4-88 years). The lung was the predominant site treated (50%), followed by intra-abdominal (13%) and soft tissue (11%). Two-year cumulative incidences of LR for surgery and SBRT were 14.8% (95% confidence interval [CI], 11.6%-18.5%) and 1.7% (95% CI, 0.1%-8.2%), respectively (P = .003). Local recurrence occurred in 72 (16.5%) of 437 tumors treated with surgery and 2 (2.3%) of 88 tumors treated with SBRT. The adjusted hazard ratio for LR of lesions treated surgically was 11.5 (P = .026) when controlling for tumor size and tumor site. Median OS was 29.8 months (95% CI, 25.6-40.9 months). There were 47 surgical complications among a total of 275 procedures (18%). Of 58 radiation treatment courses, radiation-related toxic effects were reported during the treatment of 7 lesions (12%), and none were higher than grade 2. Conclusions We observed excellent local control among patients selected for treatment with SBRT for metastatic sarcoma, with no evidence of an increase in LR after SBRT compared with surgical management. Further investigation is necessary to better define the most appropriate local control strategies for metastatic sarcoma. Traditional management of metastatic sarcoma primarily relies on systemic therapy, with surgery often used for tumor control. We analyzed the rates of recurrence, overall survival, and treatment complications in patients undergoing either surgical resection or stereotactic body radiation therapy (SBRT) for metastatic sarcoma of the bone and/or soft tissue. The records of patients with metastatic sarcoma between 2009 and 2020 were reviewed. Local recurrence (LR) was defined as tumor growth or recurrence at the tumor site. Cumulative LR incidence was analyzed accounting for the competing risk of death, and groups were compared using the Gray test. Overall survival (OS) was assessed using the Kaplan-Meier method and log-rank test. Hazard ratios were determined using the Cox proportional hazards model. A total of 525 metastatic lesions in 217 patients were analyzed. The mean age of patients was 57 years (range, 4-88 years). The lung was the predominant site treated (50%), followed by intra-abdominal (13%) and soft tissue (11%). Two-year cumulative incidences of LR for surgery and SBRT were 14.8% (95% confidence interval [CI], 11.6%-18.5%) and 1.7% (95% CI, 0.1%-8.2%), respectively (P = .003). Local recurrence occurred in 72 (16.5%) of 437 tumors treated with surgery and 2 (2.3%) of 88 tumors treated with SBRT. The adjusted hazard ratio for LR of lesions treated surgically was 11.5 (P = .026) when controlling for tumor size and tumor site. Median OS was 29.8 months (95% CI, 25.6-40.9 months). There were 47 surgical complications among a total of 275 procedures (18%). Of 58 radiation treatment courses, radiation-related toxic effects were reported during the treatment of 7 lesions (12%), and none were higher than grade 2. We observed excellent local control among patients selected for treatment with SBRT for metastatic sarcoma, with no evidence of an increase in LR after SBRT compared with surgical management. Further investigation is necessary to better define the most appropriate local control strategies for metastatic sarcoma." @default.
• W4281562082 created "2022-05-27" @default.
• W4281562082 creator A5000234599 @default.
• W4281562082 creator A5002172916 @default.
• W4281562082 creator A5002961787 @default.
• W4281562082 creator A5022982759 @default.
• W4281562082 creator A5026412755 @default.
• W4281562082 creator A5028423880 @default.
• W4281562082 creator A5042159358 @default.
• W4281562082 creator A5060290359 @default.
• W4281562082 creator A5060528631 @default.
• W4281562082 creator A5066965224 @default.
• W4281562082 creator A5074491162 @default.
• W4281562082 creator A5090006346 @default.
• W4281562082 date "2022-11-01" @default.
• W4281562082 modified "2023-10-16" @default.
• W4281562082 title "Local Control Outcomes Using Stereotactic Body Radiation Therapy or Surgical Resection for Metastatic Sarcoma" @default.
• W4281562082 cites W1581688971 @default.
• W4281562082 cites W1968961961 @default.
• W4281562082 cites W1992007584 @default.
• W4281562082 cites W2022921812 @default.
• W4281562082 cites W2023026928 @default.
• W4281562082 cites W2073140442 @default.
• W4281562082 cites W2075758052 @default.
• W4281562082 cites W2077514628 @default.
• W4281562082 cites W2096998881 @default.
• W4281562082 cites W2185023695 @default.
• W4281562082 cites W2555152066 @default.
• W4281562082 cites W2800839532 @default.
• W4281562082 cites W3100432726 @default.
• W4281562082 cites W3108567236 @default.
• W4281562082 cites W3118637286 @default.
• W4281562082 cites W3158959878 @default.
• W4281562082 cites W4252684946 @default.
• W4281562082 cites W4293241248 @default.
• W4281562082 doi "https://doi.org/10.1016/j.ijrobp.2022.05.017" @default.
• W4281562082 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35643255" @default.
• W4281562082 hasPublicationYear "2022" @default.
• W4281562082 type Work @default.
• W4281562082 citedByCount "4" @default.
• W4281562082 countsByYear W42815620822023 @default.
• W4281562082 crossrefType "journal-article" @default.
• W4281562082 hasAuthorship W4281562082A5000234599 @default.
• W4281562082 hasAuthorship W4281562082A5002172916 @default.
• W4281562082 hasAuthorship W4281562082A5002961787 @default.
• W4281562082 hasAuthorship W4281562082A5022982759 @default.
• W4281562082 hasAuthorship W4281562082A5026412755 @default.
• W4281562082 hasAuthorship W4281562082A5028423880 @default.
• W4281562082 hasAuthorship W4281562082A5042159358 @default.
• W4281562082 hasAuthorship W4281562082A5060290359 @default.
• W4281562082 hasAuthorship W4281562082A5060528631 @default.
• W4281562082 hasAuthorship W4281562082A5066965224 @default.
• W4281562082 hasAuthorship W4281562082A5074491162 @default.
• W4281562082 hasAuthorship W4281562082A5090006346 @default.
• W4281562082 hasConcept C120665830 @default.
• W4281562082 hasConcept C121332964 @default.
• W4281562082 hasConcept C126322002 @default.
• W4281562082 hasConcept C126838900 @default.
• W4281562082 hasConcept C136948725 @default.
• W4281562082 hasConcept C141071460 @default.
• W4281562082 hasConcept C142724271 @default.
• W4281562082 hasConcept C207103383 @default.
• W4281562082 hasConcept C2778256501 @default.
• W4281562082 hasConcept C2778629024 @default.
• W4281562082 hasConcept C2911091166 @default.
• W4281562082 hasConcept C44249647 @default.
• W4281562082 hasConcept C50382708 @default.
• W4281562082 hasConcept C509974204 @default.
• W4281562082 hasConcept C61511704 @default.
• W4281562082 hasConcept C71924100 @default.
• W4281562082 hasConcept C88879693 @default.
• W4281562082 hasConceptScore W4281562082C120665830 @default.
• W4281562082 hasConceptScore W4281562082C121332964 @default.
• W4281562082 hasConceptScore W4281562082C126322002 @default.
• W4281562082 hasConceptScore W4281562082C126838900 @default.
• W4281562082 hasConceptScore W4281562082C136948725 @default.
• W4281562082 hasConceptScore W4281562082C141071460 @default.
• W4281562082 hasConceptScore W4281562082C142724271 @default.
• W4281562082 hasConceptScore W4281562082C207103383 @default.
• W4281562082 hasConceptScore W4281562082C2778256501 @default.
• W4281562082 hasConceptScore W4281562082C2778629024 @default.
• W4281562082 hasConceptScore W4281562082C2911091166 @default.
• W4281562082 hasConceptScore W4281562082C44249647 @default.
• W4281562082 hasConceptScore W4281562082C50382708 @default.
• W4281562082 hasConceptScore W4281562082C509974204 @default.
• W4281562082 hasConceptScore W4281562082C61511704 @default.
• W4281562082 hasConceptScore W4281562082C71924100 @default.
• W4281562082 hasConceptScore W4281562082C88879693 @default.
• W4281562082 hasIssue "4" @default.
• W4281562082 hasLocation W42815620821 @default.
• W4281562082 hasLocation W42815620822 @default.
• W4281562082 hasOpenAccess W4281562082 @default.
• W4281562082 hasPrimaryLocation W42815620821 @default.
• W4281562082 hasRelatedWork W1982438630 @default.
• W4281562082 hasRelatedWork W2150538964 @default.
• W4281562082 hasRelatedWork W2411966289 @default.
• W4281562082 hasRelatedWork W2417044707 @default.
• W4281562082 hasRelatedWork W3030027916 @default.

• next